Mass spectrometry vendors pushed new hardware and workflows—such as the Orbitrap Astral Zoom MS—raising throughput to hundreds of samples per day and improving depth to measure ~8,000 proteins per run. These upgrades aim to make proteomics and metabolomics viable at cohort scale for clinical and translational studies. Faster scan rates, ion pre‑accumulation and enhanced data pipelines reduce the historic throughput bottleneck. The advances position mass spec as a practical bridge to clinical multiomic trials and biomarker discovery, though adoption will require standardized sample prep, robust QC and integration with bioinformatics pipelines.